Bio-Works confirms order from new production customer for oligonucleotide manufacturing
Today, Bio-Works Technologies AB has confirmed an order worth 2.3 MSEK for WorkBeads chromatography resins to be used in the manufacture of oligonucleotides. The customer is an American contract manufacturer who offers cGMP manufacturing to other pharmaceutical companies. They are part of a larger American conglomerate with 17 000 employees globally. Delivery is planned early in the third quarter of this year.
”For over a year, we have said that there are opportunities for Bio-Works to expand on our success with peptides in the oligo market. This order confirms that our theory is correct,” says Jonathan Royce, CEO at Bio-Works.
Oligonucleotides are a new type of pharmaceutical which has broken through in recent years. They are comprised of short DNA- or RNA-molecules and can be targeted against specific genes which increase the chance of illness or which impact the development of illness. Last year, the European Medicines Agency approved the cholesterol-reducing oligonucleotide therapy Inklisiran. The sales of oligonucleotide therapies amounted to 0.98 billion USD 2021 and are expected to grow 13% per year until 2025.
This disclosure contains information that Bio-Works Technologies AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 10-06-2022 09:22 CET.
For more information, please visit the Bio-Works homepage at, www.bio-works.com or contact: Jonathan Royce, CEO, e-mail: jonathan.royce@bio-works.com, phone: +46 70 1434143.
About Bio-Works
Bio-Works enables scientists to achieve their purification goals, from laboratory research to large scale bioprocess production. Our vision is a biotech industry that embraces, develops and builds on new methods and novel ideas. WorkBeads™, Bio-Works’ next-generation, agarose-based products, are used to purify proteins, peptides and other biomolecules, resulting in purer therapies and safer diagnostics. Through collaboration with customers and partners, we develop purification solutions that make important medicines available and accessible to everyone.
Bio-Works’ headquarters, with R&D and manufacturing, is located in Uppsala Business Park in Uppsala, Sweden. We supply products globally, through a combination of direct sales and via distributors in Europe, North America and Asia. The company is certified according to the ISO 9001:2015 quality management system. Bio-Works is listed on Nasdaq First North (“BIOWKS”), and FNCA Sweden AB, +46 (0) 8-528 00 399, info@fnca.se, is appointed Certified Adviser. For more information, www.bio-works.com.